Shares of Vertex (NASDAQ:VRTX) skyrocketed today, on very exciting news coming from a phase 2 trial of one of the company's cystic fibrosis drugs. Is Vertex the next big biotech that investors need to be a part of? In this video, Motley Fool health-care analyst David Williamson talks about the phase 2 results, and why investors should stand up and pay attention, and tells us where the company could go in 2013.
David Williamson has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.